cagrilintide semaglutide combination cagrisema phase 3 2025 CagriSema: a novel dual-pathway approach to target obesity and its complications cagrilintide phase 3 Coadministered and

Step 3: Select starting dose Begin at the lower end of the recommended range for your chosen method

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G

Top Research Studies on GLP-1s and Cardiovascular Outcomes The November 2023 issue of The New England Journal of Medicine shared results from a research study (SELECT) involving 17,000 patients that showed the use of semaglutide was linked to a 20% reduction in the risk of major adverse cardiovascular events such as heart disease, stroke and peripheral arterial disease in patients who had previously been diagnosed with heart disease

Trials like FLOW (semaglutide) are actively investigating and further solidifying the role of GLP-1s in preserving kidney function in T2DM patients